The Role of CD200 in Differentiation Between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms in Sudanese Patients (original) (raw)
Related papers
2015
Objective: To determine the clinical and epidemiological and laboratory characteristics of Chronic-B Lymphocytic Leukemia (B-CLL) and other chronic-B lymphoproliferative malignancies (B-CLM), including the expression of CD200. Methods: A retrospective and descriptive study of the case series type conducted at the Foundation HEMOPE with adults of both sexes diagnosed with B-CLL and other B-CLMs. Results: 95 patients were assessed, of whom 64 had B-CLL and 31 other B-CLMs. The average age was 70.40 years in BCLL and 61.80 years in the other B-CLMs. Adenomegaly was more frequent in patients with B-CLL, whereas splenomegaly and B symptoms were more frequently observed in other B-CLMs. In patients with B-CLL, the average of leukocytes was 82,607/ul (80.26% lymphocytes and 13.33% neutrophils), whereas in other B-CLMs, the average of leukocytes was 63,614 / ul (70.32% lymphocytes and14.67% neutrophils) but this was statistically significant only in the observation of greater lymphocytosis ...
American journal of clinical pathology, 2014
To analyze CD200 expression by flow cytometry in a large series of B-cell neoplasms in a variety of tissue types in comparison with benign B-lineage cells. We measured CD200 expression levels in 505 peripheral blood (PB), bone marrow (BM), and lymphoid tissue biopsy specimens, including 364 cases positive for B-cell leukemias and lymphomas. CD200 expression in chronic lymphocytic leukemia cases was as bright as or brighter than normal PB B cells in nearly all cases, while mantle cell lymphoma (MCL) cases were usually dim or negative. However, rare MCL cases (about 5%) were moderately bright for CD200. Marginal zone lymphomas varied by subtype, with nodal cases brighter, splenic cases dimmer, and extranodal cases heterogeneous for CD200 expression. Follicular lymphoma (FL) cells were brighter for CD200 in BM specimens than in lymph nodes. In some BM specimens, dim CD200 could distinguish FL cells from background hematogones. Large B-cell lymphomas of the non-germinal center type tend...
International Journal of Hematology-Oncology and Stem Cell Research, 2020
Background: The present work aimed to investigate the expression of CD160/ CD200 in CLL and other mature B-cell neoplasms (MBN) and their use as an additional diagnostic tool for differentiating CLL from other MBN. Materials and Methods: Using flow cytometry, we detected the expression of CD160 &CD200 on B-cells from 30 CLL patients, 30 other MBN patients in addition to 20 controls. CDs160/200 measurements were determined as a percentage expression (≥20% was considered positive) and as a ratio of the mean fluorescence intensities (MFIR) of leukemic cells/controls and were considered positive when the ratios were ≥2 and 20, respectively. Results: 90% and 100% of the CLL group expressed CDs160/200 in comparison to 60% and 63.3% of other MBN (p=0.007, p<0.001), respectively. By MFIR, 96.7% and 50% of our CLL group expressed CDs160/200 in comparison to 76.7% and 30% of other MBN, respectively. CDs160/ 200 were not expressed on the controls. Positive co-expression of CD160 and CD200 wa...
Asian Pacific Journal of Cancer Prevention
weak expression of CD20. MCL is usually CD23negative and CD20 strongly positive. However, in some cases, CD23 is expressed in MCL and is lacking in CLL leading to misdiagnosis (Barna et al., 2008). A membrane glycoprotein expressed in all CD19+ B lymphocytes and some of the T is known as CD200. It is not expressed in natural killer cells, monocytes, granulocytes or platelets. This glycoprotein previously named OX2 is also expressed in myeloma plasma cells and acute myeloid leukemia (Moreaux et al., 2008). Some studies have evaluated the role of CD200 expression in the differential diagnosis of CLL and other mature B cell lymphoproliferative disorders
Cytometry Part B: Clinical Cytometry, 2013
Background: Multiparameter flow cytometry is a useful tool for the diagnostic evaluation of mature Bcell neoplasms (MBN). Recently, it has been shown that CD200 may improve the distinction between chronic lymphocytic leukemia (CLL; CD2001) and mantle cell lymphoma (MCL; CD2002), but the role of CD200 expression in atypical CLL and other MBN remains to be established. Methods: To address this issue, we investigated the expression of CD200 in 159 consecutive cases of MBN. Results: CD200 was strongly expressed in CLL and was revealed to be an excellent marker to distinguish CLL from MCL, even in cases of atypical CLL. However, lack of CD200 was not an exclusive finding of MCL, being also observed in other MBNs. Furthermore, CD200 was highly expressed in hairy cell leukemia, being useful in the differential diagnosis of lymphomas with villous lymphocytes. Herein, we propose an algorithm to classify CD51 MBNs based on the expression of CD200, CD11c, heavy chain immunoglobulins, and Matutes score. Conclusions: These results expand the understanding of the CD200 expression in MBNs, giving further support for the inclusion of this marker in the routine investigation by flow cytometry. V
Leukemia Research, 2009
Chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) share many features and their differential diagnosis may be challenging, especially when a leukemic picture alone is present. Monoclonal antibody panels are often useful, with CD23 being the most reliable. However, MCL diagnosis should be confirmed by immunohistochemical cyclin D1 detection, sometimes with equivocal or even negative results. Other cytofluorimetric, cytogenetics or molecular techniques are reliable but not widely available.
2012
CD20 and CD19 are known to common B cell markers used widely in the identification of B cells. They are also available in most flow cytometry laboratories which is study of B cell disorders, so our choice of these CDs is to shed light on their expression in normal pattern and find out whether the way the pattern of expression in the cells may be useful in the diagnosis of some B cell disorders, especially to differentiate between chronic lymphocytic leukemic (CLL) and Non-Hodgkin lymphoma (NHL) , To study these changes we depend on some flow cytometric parameters like the percentage of positive cells, mean fluorescence intensity and the positive peak width. Hundred and thirteen samples were studied, 8 samples of them were normal control. The samples nature were venous blood, bone marrow aspiration samples and lymph node samples. We were found that the percentage of CD20 or/and CD19 which reflect the total B cells in the sample is the best parameter for indication of presence of B ce...
American Journal of Clinical Pathology, 2012
The membrane glycoprotein MRC OX-2 (CD200) is expressed in several lymphoid malignancies. However, the diagnostic utility and potential prognostic importance of CD200 expression have not been rigorously examined. We show that CD200 is uniformly expressed in chronic lymphocytic leukemia (CLL) and absent in mantle cell lymphoma (MCL). Importantly, expression of CD200 is retained even in those CLLs with immunophenotypic aberrancies, making CD200 a particularly useful marker for discrimination between these cases and MCL. CD200 is expressed in nearly all precursor B lymphoblastic leukemias, with aberrant over-or underexpression when compared to normal B-cell progenitors in 55% of cases. Over 70% of plasma cell myelomas (PCMs) expressed CD200, and loss of CD200 expression in PCM may be associated with more clinically aggressive disease. In summary, CD200 is expressed in several hematolymphoid neoplasms. Analysis of its expression has several diagnostic, and potentially prognostic, applications in the flow cytometric evaluation of lymphoid malignancies.
Levels of expression of CD19 and CD20 in chronic B cell leukaemias
Journal of Clinical Pathology, 1998
Aims-To investigate whether the antigen levels of the B cell lineage markers CD19 and CD20 can distinguish between normal and neoplastic B cells or characterise distinct expression patterns among the chronic B cell leukaemias. Methods-Peripheral blood cells from 70 patients with B cell disorders and 17 healthy donors were analysed by quantitative flow cytometry. Direct immunofluorescence staining was performed with phycoerythrin conjugated CD19 and CD20 monoclonal antibodies. Standard microbeads with diVerent capacities to bind mouse immunoglobulins were used to convert the mean fluorescence intensity (MFI) values into number of antigen molecules/cell, expressed as antibody binding capacity (ABC). Results-CD19 and CD20 ABC values in leukaemic B cells diVered from those of normal blood B lymphocytes. The results identified distinct profiles of CD19 and CD20 expression in the various types of B cell leukaemias. In all leukaemias studied except hairy cell leukaemia (HCL), CD19 expression was significantly lower than the mean (SD) value in normal B cells (22 (7) × 10 3 molecules/cell), as follows: chronic lymphocytic leukaemia (CLL), 13 (7) ×10 3 ; B prolymphocytic leukaemia (B-PLL), 16 (9) ×10 3 ; splenic lymphoma with villous lymphocytes (SLVL), 15 (11) × 10 3 ; mantle cell lymphoma (MCL), 10 (7) × 10 3. In HCL there was strong CD19 expression (38 (16) × 10 3). In contrast, the level of expression of membrane CD20 was higher than the mean (SD) value in normal B cells (94 (16) × 10 3 molecules/ cell) in MCL (123 (51) × 10 3); B-PLL (129 (47) × 10 3); SLVL (167 (72) × 10 3); and HCL (312 (110) × 10 3); while it was significantly lower (65 (11) × 10 3) in CLL compared with normal B cells and the other B cell leukaemias. Conclusions-Quantitative determination of CD19 and CD20 may provide useful diagnostic information for the study of B lymphoproliferative disorders.